Biopsy devices are used to remove a piece of tissue or cells from the body to analyze in the laboratory for the presence of a disease. According to Marketstack, the Global Breast Biopsy Market is expected to grow considerably during the forecasted period. Factors such as the increase in the prevalence of cancer are expected to drive the Breast Biopsy Market in the forecasted period. Further, the increase in the inclination towards minimally invasive surgeries among the population owing to the quick recovery and less pain is expected to drive the Breast Biopsy Market in the forecasted period. Furthermore, the broad and intensive research environment, which has contributed to developing more precise and minimally invasive processes for early identification of mammary cancer, is predicted to drive the Breast Biopsy Market in the forecasted period. However, the expensive expenses of devices and a scarcity of qualified specialists capable of carrying out essential and advanced cancer detection processes are expected to drive the Breast Biopsy Market in the forecast period.

The growing prevalence of breast cancer will drive the demand for breast biopsy devices shortly. The burden of breast cancer is increasing owing to the growing population along with the changing lifestyle and excessive consumption of tobacco and alcohol. Breast cancer is a vital public health issue in low- and middle-income countries. Besides, factors contributing to the existing disease burden are poor quality control, low mammography coverage, insufficient physical and human resources for clinical care, and limited access to diagnosis and treatment. Early cancer detection is made possible by breast biopsy technology, which aids in the treatment of many cancer patients. Lack of accuracy in identifying cancerous tissues is blamed for the majority of cancer-related deaths. The bio-imaging sector has been fully converted by imaging-based breast biopsy instruments, which have considerably increased the usage of molecular images. Growing developments in molecular imaging-related technologies are critical to the market's expansion. A biopsy is a confirming process that helps in early cancer/tumour diagnosis, which promotes quick recovery, elevates survival, and reduces morbidity and death. Medical professionals advise a liquid breast biopsy for the early diagnosis of breast cancer. Various governmental and private organizations, commercial enterprises, and medical facilities are working on innovative initiatives to surge public awareness of breast cancer and the benefits of early detection on health.

Furthermore, the growing prevalence of benign breast diseases such as fibroadenoma and cysts, growing demand for personalized medicine, a rising number of initiatives to promote breast cancer screening, such as mammography screening programs, rising incidence of breast cancer in men, growing healthcare expenditure and increasing number of strategic partnerships and collaborations between healthcare providers and breast biopsy companies promote the market's growth rate. Factors include the growing demand for image-guided biopsies, such as ultrasound-guided and MU-guided biopsies, using the adoption of breast tomosynthesis, favourable reimbursement policies for breast biopsy procedures, the ever-increasing need for core needle biopsies and growing demand for liquid biopsy support the growth rate of the breast biopsy device market.

North America, combining the U.S. and Canada, is predicted to have the most significant share of the breast biopsy devices market. The vital market share of the North American region can be accredited to several critical factors, including continuous technological advancements, rising incidence rates of breast cancer, favourable reimbursement scenarios, and the enactment of new breast density notification laws in the U.S. These factors have played a pivotal role in fueling the dominant position of the North American market, creating favourable business opportunities for companies operating in the region. Robotic platforms, surgical navigation systems, and artificial intelligence are highly required due to their accuracy and efficiency. Using robotics in MRI systems can localize breast abnormalities and improve procedural efficacy. Vendors are also developing AI-integrated solutions to help doctors analyze breast cancer and reduce human errors. Core needle biopsy has witnessed a surge in demand due to its minimally invasive nature, higher diagnostic accuracy, and reduced patient discomfort compared to traditional surgical biopsies. This technique involves using a more extensive, hollow-core needle to pick a tissue sample from the breast lesion, allowing for a more comprehensive analysis. Core biopsy needle offers several benefits, such as shorter recovery time, lower cost, and minimal scarring, contributing to its increasing adoption by healthcare professionals and patients. Hospitals and clinics serve as primary healthcare settings where breast biopsies are routinely performed. These facilities are equipped with advanced imaging technologies, such as mammography, ultrasound, and MRI, which aid in detecting and localizing breast abnormalities. Moreover, hospitals and clinics have skilled healthcare professionals, including radiologists, pathologists, and surgeons, trained in performing breast biopsies and interpreting the results. The availability of comprehensive healthcare services, multidisciplinary care teams, and the ability to provide a wide range of treatment options contribute to the prominence of hospitals and clinics in the global market.

The market key players are Scion Medical Technologies LLC, STERYLAB S.r.l ., ARGON MEDICAL, Danaher, and Cianna Medical.

In January 2023, Hologic Inc. received FDA Approval for New Breast Biopsy System: Hologic Inc., a leading company in the breast biopsy market, announced that it has acquired approval from the U.S. FDA for its innovative Affirm Prone Biopsy System. The system offers high-precision, minimally invasive breast biopsies, aiming to provide improved patient comfort and enhanced diagnostic accuracy.

In March 2022, C. R. Bard, Inc.. announced its acquisition by B.D.: C. R. Bard, Inc., a prominent player in the breast biopsy market, finalized its acquisition by Becton, Dickinson and Company (B.D.). This acquisition strengthens B.D.'s presence in the sector by incorporating C. R. Bard's extensive medical device and solutions range. The merger aims to offer breast cancer patients comprehensive diagnostic and treatment options while driving further innovation and market expansion.

Global Breast Biopsy Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Breast Biopsy Market by segmenting based on Product (Biopsy Needles, Biopsy Table, Biopsy Wires, Guidance Systems, Others), Technique Type (Fine Needle Aspiration Biopsy, Core Needle Biopsy, Biopsy Markers, MRi-guided core Needle Biopsy, Surgical Biopsy, Wire Localization, Sentinel Node Biopsy), Guidance Technology (Fine Ultrasound-Guided, Mammography-Guided Magnetic Resonance, CT-Guided Biopsy, Other Image-Guided Breast Biopsy), End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Other), and Geography (Asia-Pacific, North America, Europe, South America, and Middle East & Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers emerging market trends, development, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.